Cellular metabolic reprogramming and intrinsic immune escape are key features of pancreatic cancer, and GOT2, as a metabolic enzyme, bridges organically the two, presenting a broader prospect for targeting GOT2 to treat pancreatic cancer. Here, GOT2 is linked to pancreatic neoplasm.